Management and treatment of multidrug-resistant tuberculosis

C. Lange (Borstel, Germany)

Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management

Session: Tuberculosis: latest advances and challenges in patient management
Session type: Lunchtime session
Number: 3175

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Lange (Borstel, Germany). Management and treatment of multidrug-resistant tuberculosis. International Congress 2019 – Tuberculosis: latest advances and challenges in patient management

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005
Management of MDR tuberculosis Source: Short video discussion 2021 Year: 2021
Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001
Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003
Treatment of drug-susceptible and drug-resistant tuberculosis Source: Eur Respir Monogr 2018; 82: 152-178 Year: 2018
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013
Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012
Analysis of multidrug-resistant tuberculosis Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017
Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis Source: Annual Congress 2009 - Priorities in tuberculosis research Year: 2009
Treatment results of multidrug-resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 11s Year: 2006
Epidemiology of TB Source: Eur Respir Mon 2012; 58: 14-25 Year: 2012
Comorbidome in multidrug-resistant tuberculosis patients Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
Linezolid in multidrug-resistant tuberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 485s Year: 2004
Predictors of treatment outcome in multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Recurrence after successful treatment among patients with multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004
The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
The efficiency of surgical treatment for multidrug-resistant pulmonary and pleural tuberculosis Source: International Congress 2016 – Surgical strategy for complex diseases Year: 2016